Ampelopsin sodium exhibits antitumor effects against bladder carcinoma in orthotopic xenograft models

Anti-Cancer Drugs

Volumn 23, Issue 6, 2012, Pages 590-596

  Zhang, Baolai ^a,b,c   Dong, Shuhong ^a,b   Cen, Xiaobo ^c   Wang, Xiao ^a,b   Liu, Xia ^a,b   Zhang, Hongxia ^a,b   Zhao, Xin ^a,b   Wu, Yongjie ^a,b  

^a LANZHOU UNIVERSITY   (China)

^b Key Laboratory of Preclinical Study for New Drugs of Gansu Province   (China)

^c SICHUAN UNIVERSITY   (China)

Author keywords

ampelopsin sodium; antitumor activity; bladder cancer; orthotopic xenograft model; pharmacokinetics

Indexed keywords

AMP NA; AMPELOPSIN SODIUM; ANTINEOPLASTIC AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BAGG ALBINO MOUSE; BLADDER CARCINOMA; CARCINOMA CELL; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFECT; DRUG EXCRETION; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SARCOMA CELL; SINGLE DRUG DOSE; SWISS WEBSTER MOUSE; TUMOR XENOGRAFT; URINARY EXCRETION;

ADMINISTRATION, INTRAVESICAL; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL CYCLE CHECKPOINTS; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLAVONOIDS; HUMANS; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENOUS; MICE; MICE, INBRED BALB C; SARCOMA; URINARY BLADDER NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84862796733     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32835019f9     Document Type: Article

References (31)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics. CA Cancer J Clin 2010; 60:277-300.
2. Morse MA, Stoner GD. Cancer chemoprevention: principles and prospects. Carcinogenesis 1993; 14:1737-1746.
3. Tyagi A, Agarwal C, Harrison G, Glode LM, Agarwal R. Silibinin causes cell cycle arrest and apoptosis in human bladder transitional cell carcinoma cells by regulating CDKI-CDK-cyclin cascade, and caspase 3 and PARP cleavages. Carcinogenesis 2004; 25:1711-1720.
4. Herr HW, Wartinger DD, Fair WR, Oettgen HF. Bacillus Calmette-Guerin therapy for superficial bladder cancer: a 10-year follow-up. J Urol 1992; 147:1020-1023.
5. Lamm DL, Thor DE, Harris SC, Reyna JA, Stogdill VD, Radwin HM. Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer. J Urol 1980; 124:38-40.
6. Wu Q, Mahendran R, Esuvaranathan K. Nonviral cytokine gene therapy on an orthotopic bladder cancer model. Clin Cancer Res 2003; 9:4522-4528.
7. Ohe H, Watanabe H, Mishina T, Kojima M, Nakagawa S. Intravesical instillation of adriamycin for bladder tumors. Cancer Chemother Pharmacol 1992; 30 (Suppl):S45-S49.
8. Qian L, Ding H, Zhou J, Wang X, Shao P, Wu S, et al. Intravesical N-(4-hydroxyphenyl) retinamide and adriamycin induces apoptosis in bladder cancer. Front Biosci 2006; 11:2045-2051.
9. Naito S, Kotoh S, Omoto T, Osada Y, Sagiyama K, Iguchi A, et al. Prophylactic intravesical instillation chemotherapy against recurrence after a transurethral resection of superficial bladder cancer: a randomized controlled trial of doxorubicin plus verapamil versus doxorubicin alone. Cancer Chemother Pharmacol 1998; 42:367-372.
10. Naito S, Iguchi A, Sagiyama K, Ariyoshi A, Osada Y, Omoto T, et al. Significance of the preoperative intravesical instillation of doxorubicin and the oral administration of 5-fluorouracil in preventing recurrence after a transurethral resection of superficial bladder cancer. Int J Urol 1997; 4:352-357.
11. DeVita VT Jr, Chu E. A history of cancer chemotherapy. Cancer Res 2008; 68:8643-8653.
12. Briasoulis E, Golfinopoulos V, Karina M, Papakostas P, Pavlidis N, Fountzilas G. Phase I trial of weekly irinotecan and paclitaxel combined with carboplatin in patients with advanced cancer: a Hellenic Cooperative Oncology Group Study. Anticancer Drugs 2010; 21:785-789.
13. Alberts DS, Dorr RT. New perspectives on an old friend: optimizing carboplatin for the treatment of solid tumors. Oncologist 1998; 3:15-34.
14. Thiery-Vuillemin A, Dobi E, Nguyen T, Royer B, Montange D, Maurina T, et al. Duration: escalation study of oral etoposide with carboplatin in patients with varied solid tumors. Anticancer Drugs 2010; 21:958-962.
15. Liu DY, Ye JT, Yang WH, Yan J, Zeng CH, Zeng S. Ampelopsin, a small molecule inhibitor of HIV-1 infection targeting HIV entry. Biomed Environ Sci 2004; 17:153-164.
16. Kotake M, Kubota T. About ingredients from Ampelopsis meliaefolia Kudo (Haku-Tya). Liebigs Annalen der Chemie 1940; 544:253-271.
17. Wang MX, Liu WZ, Huang AD, Luo LQ, Zhou AQ. Isolation and identification on the consistuents of flavonoids in Radix Ampelopsis Cantoniensis. J Chin Med Mater 1989; 12:28-30, (in Chinese).
18. Liu DY, Luo M, Xie BF, Feng GK, Zhu XF, Liu ZC. Antitumor effects of ampelopsin. Chin J Cancer 2001; 20:1372-1375, (in Chinese).
19. Liu DY, Qiu MQ, Liang TY. Extraction and isolation of Ampelopsin from Ampelopsis Cantoniensis Planch and its inhibitory effect on B16 melanoma. Acad J SUMS 1999; 20:127-129, (in Chinese).
20. Tan GY, Zhang MH, Feng JH, Han AY, Zheng SS, Xie P. Effects of pretreatment by the flavanol ampelopsin on porcine kidney epithelial cell injury induced by hydrogen peroxide. Agric Sci China 2010; 9:598-604.
21. Bi S, Liu JR, Li Y, Wang Q, Liu HK, Yan YG, et al. Gamma-tocotrienol modulates the paracrine secretion of VEGF induced by cobalt(II) chloride via ERK signaling pathway in gastric adenocarcinoma SGC-7901 cell line. Toxicology 2010; 274:27-33.
22. Aghazadeh-Habashi A, Sattari S, Pasutto F, Jamali F. High performance liquid chromatography determination of glucosamine in rat plasma. J Pharm Pharm Sci 2002; 5:158-161.
23. Chin J, Kadhim S, Garcia B, Kim YS, Karlik S. Magnetic resonance imaging for detecting and treatment monitoring of orthotopic murine bladder tumor implants. J Urol 1991; 145:1297-1301.
24. Chong L, Ruping Y, Jiancheng B, Guohong Y, Yougang F, Jiansong W, et al. Characterization of a novel transplantable orthotopic murine xenograft model of a human bladder transitional cell tumor (BIU-87). Cancer Biol Ther 2006; 5:394-398.
25. Bello E, Colella G, Scarlato V, Oliva P, Berndt A, Valbusa G, et al. E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res 2011; 71:1396-1405.
26. Zhang B, Gao B, Dong S, Zhang Y, Wu Y. Anti-tumor efficacy and pre-clinical immunogenicity of IFNa2a-NGR. Regul Toxicol Pharmacol 2011; 60:73-78.
27. Li Z, Liu W, Mo B, Hu C, Liu H, Qi H, et al. Caffeine overcomes genistein-induced G2/M cell cycle arrest in breast cancer cells. Nutr Cancer 2008; 60:382-388.
28. Soloway MS, Masters S. Urothelial susceptibility to tumor cell implantation: influence of cauterization. Cancer 1980; 46:1158-1163.
29. Gunther JH, Jurczok A, Wulf T, Brandau S, Deinert I, Jocham D, et al. Optimizing syngeneic orthotopic murine bladder cancer (MB49). Cancer Res 1999; 59:2834-2837.
30. Banks MD, Pontes JE, Izbicki RM, Piearce JM Jr. Topical instillation of doxorubicin hydrochloride in the treatment of recurring superficial transitional cell carcinoma of the bladder. J Urol 1977; 118:757-760.
31. Mishina T, Fujiwara T, Miyakoda K, Araki H, Kobayashi T, Saitoh M, et al. Adriamycin instillation therapy for bladder tumors. Tohoku J Exp Med 1979; 127:339-343.